サマリー

北米の水頭症市場は、2023年の791,635.49千米ドルから2031年には1,278,950.74千米ドルに達すると予測され、2024年から2031年の予測期間における年平均成長率は6.4%で推移すると予測される。
市場セグメント
北米の水頭症市場：タイプ別（先天性水頭症、後天性水頭症、正常圧水頭症、外水頭症）、診断・治療別（診断と治療）、エンドユーザー別（病院、診療所、診断センター、学術機関・研究機関）、国別（米国、カナダ、メキシコ）-産業動向と2031年までの予測
北米の水頭症市場ダイナミクスの概要

促進要因
- 神経疾患の発生率の増加
抑制要因

- 不十分な償還政策

機会

- 医療機関や政府機関による支援の拡大

市場プレイヤー

北米の水頭症市場で事業を展開する主な市場参入企業は以下の通り：

- Aesculap, Inc.
- インテグラ・ライフサイエンス
- ジー・サーギウェア社
- モレール・メディカル社
- アヌンシア社
- クリストフ・ミースケGmbH & co.KG
- KARL STORZ SE & Co.KG
- 株式会社プロテテス
- メドトロニック
- ナタス
- デスーメディカル
- ビカクシラー
- シュピーゲルベルグGmbH & Co.KG
- ソフィサ
- カネカメディックス

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 OVERVIEW OF NORTH AMERICA HYDROCEPHALUS MARKET 14
1.4 LIMITATIONS 15
1.5 MARKETS COVERED 15
2 MARKET SEGMENTATION 18
2.1 MARKETS COVERED 18
2.2 GEOGRAPHICAL SCOPE 19
2.3 YEARS CONSIDERED FOR THE STUDY 20
2.4 CURRENCY AND PRICING 20
2.5 DBMR TRIPOD DATA VALIDATION MODEL 21
2.6 MULTIVARIATE MODELLING 24
2.7 TYPE LIFELINE CURVE 24
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 25
2.9 DBMR MARKET POSITION GRID 26
2.10 VENDOR SHARE ANALYSIS 27
2.11 SECONDARY SOURCES 28
2.12 ASSUMPTIONS 28
3 EXECUTIVE SUMMARY 29
4 PREMIUM INSIGHTS 31
5 NORTH AMERICA HYDROCEPHALUS MARKET: REGULATIONS 32
5.1 REGULATIONS IN U.S. 32
5.2 REGULATIONS IN EUROPE 32
5.3 REGULATIONS IN INDIA 32
5.4 REGULATIONS IN JAPAN 33
5.5 REGULATIONS IN BRAZIL 33
6 MARKET OVERVIEW 34
6.1 DRIVERS 36
6.1.1 INCREASING INCIDENCE OF NEUROLOGICAL CONDITIONS 36
6.1.2 GROWING NUMBER OF NEW-BORNS AFFECTED BY HYDROCEPHALUS 36
6.1.3 INCREASING ADAPTATION OF ADVANCED PROGRAMMABLE VALVES 37
6.1.4 RISING AWARENESS ABOUT HYDROCEPHALUS 37
 
6.2 RESTRAINTS 38
6.2.1 POOR REIMBURSEMENT POLICIES 38
6.2.2 DELETERIOUS COMPLICATIONS WITH HYDROCEPHALUS DEVICES 38
6.3 OPPORTUNITIES 39
6.3.1 GROWING SUPPORT BY HEALTHCARE ORGANIZATIONS AND GOVERNMENT BODIES 39
6.3.2 GROWING HEALTHCARE EXPENDITURE 40
6.3.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS 40
6.4 CHALLENGES 41
6.4.1 HIGH PRODUCT RECALL SCENARIO 41
6.4.2 LACK OF ACCESSIBILITY OF HYDROCEPHALUS PRODUCTS 41
7 NORTH AMERICA HYDROCEPHALUS MARKET, BY TYPE 42
7.1 OVERVIEW 43
7.2 CONGENITAL HYDROCEPHALUS 46
7.3 ACQUIRED HYDROCEPHALUS 46
7.4 NORMAL-PRESSURE HYDROCEPHALUS 47
7.5 EX-VACUO HYDROCEPHALUS 47
8 NORTH AMERICA HYDROCEPHALUS MARKET, BY DIAGNOSTICS & TREATMENT 48
8.1 OVERVIEW 49
8.2 DIAGNOSTICS 52
8.2.1 MAGNETIC RESONANCE IMAGING (MRI) 52
8.2.2 CT SCAN – HEAD 52
8.2.3 HEAD ULTRASOUND 53
8.3 TREATMENT 53
8.3.1 SURGERY – SHUNT INSERTION, BY PRODUCT TYPE 54
8.3.1.1 HYDROCEPHALUS VALVES 54
8.3.1.2 HYDROCEPHALUS CATHETERS 54
8.3.1.2.1 ADJUSTABLE PRESSURE VALVES 54
8.3.1.2.2 FIX PRESSURE VALVES 55
8.3.2 SURGERY – SHUNT INSERTION, BY AGE GROUP 55
8.3.2.1 PEDIATRIC 55
8.3.2.2 ADULT 55
8.3.3 VENTRICULOSTOMY 55
8.3.4 MEDICATION 55
8.3.5 TREATMENT, BY AGE GROUP 56
8.3.6 INFANTS 56
8.3.7 CHILDREN 56
8.3.8 ADULTS 56
 
9 NORTH AMERICA HYDROCEPHALUS MARKET, BY END USERS 57
9.1 OVERVIEW 58
9.2 HOSPITALS 61
9.3 CLINICS 61
9.4 DIAGNOSTIC CENTERS 62
9.5 ACADEMIC INSTITUTIONS AND RESEARCH ORGANIZATIONS 62
9.5.1 HOSPITALS 63
9.5.2 AMBULATORY AND SURGICAL CENTERS 63
9.5.3 HOSPITALS 63
9.5.4 CLINICS 63
9.5.5 DIAGNOSTIC CENTER 64
9.5.6 SURGICAL CENTERS 64
9.5.7 AMBULATORY SURGICAL CENTERS 64
9.5.8 OTHERS 64
10 NORTH AMERICA HYDROCEPHALUS MARKET, BY REGION 65
10.1 OVERVIEW 66
10.2 NORTH AMERICA 69
10.2.1 U.S. 73
10.2.2 CANADA 77
10.2.3 MEXICO 81
11 NORTH AMERICA HYDROCEPHALUS MARKET, COMPANY LANDSCAPE 85
11.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 85
12 SWOT ANALYSIS 86
13 COMPANY PROFILE 87
13.1 MEDTRONIC 87
13.1.1 COMPANY SNAPSHOT 87
13.1.2 REVENUE ANALYSIS 87
13.1.3 COMPANY SHARE ANALYSIS 88
13.1.4 PRODUCT PORTFOLIO 88
13.1.5 RECENT DEVELOPMENTS 88
13.2 AESCULAP, INC. – A B. BRAUN COMPANY 89
13.2.1 COMPANY SNAPSHOT 89
13.2.2 COMPANY SHARE ANALYSIS 89
13.2.3 PRODUCT PORTFOLIO 90
13.2.4 RECENT DEVELOPMENT 90
 
13.3 INTEGRA LIFESCIENCES 91
13.3.1 COMPANY SNAPSHOT 91
13.3.2 REVENUE ANALYSIS 91
13.3.3 COMPANY SHARE ANALYSIS 92
13.3.4 PRODUCT PORTFOLIO 92
13.3.5 RECENT DEVELOPMENT 93
13.4 SPIEGELBERG GMBH & CO. KG 94
13.4.1 COMPANY SNAPSHOT 94
13.4.2 COMPANY SHARE ANALYSIS 94
13.4.3 PRODUCT PORTFOLIO 95
13.4.4 RECENT DEVELOPMENT 95
13.5 BICAKCILAR 96
13.5.1 COMPANY SNAPSHOT 96
13.5.2 COMPANY SHARE ANALYSIS 96
13.5.3 PRODUCT PORTFOLIO 97
13.5.4 RECENT DEVELOPMENTS 97
13.6 ANUNCIA INC 98
13.6.1 COMPANY SNAPSHOT 98
13.6.2 PRODUCT PORTFOLIO 98
13.6.3 RECENT DEVELOPMENT 98
13.7 CHRISTOPH MIETHKE GMBH & CO. KG 99
13.7.1 COMPANY SNAPSHOT 99
13.7.2 PRODUCT PORTFOLIO 99
13.7.3 RECENT DEVELOPMENT 100
13.8 DESU MEDICAL 101
13.8.1 COMPANY SNAPSHOT 101
13.8.2 PRODUCT PORTFOLIO 101
13.8.3 RECENT DEVELOPMENT 101
13.9 G.SURGIWEAR LTD 102
13.9.1 COMPANY SNAPSHOT 102
13.9.2 PRODUCT PORTFOLIO 102
13.9.3 RECENT DEVELOPMENT 102
13.10 HPBIO 103
13.10.1 COMPANY SNAPSHOT 103
13.10.2 PRODUCT PORTFOLIO 103
13.10.3 RECENT DEVELOPMENT 103
 
13.11 KANEKA MEDIX CORP 104
13.11.1 COMPANY SNAPSHOT 104
13.11.2 REVENUE ANALYSIS 104
13.11.3 PRODUCT PORTFOLIO 106
13.11.4 RECENT DEVELOPMENTS 106
13.12 KARL STORZ SE & CO. KG 107
13.12.1 COMPANY SNAPSHOT 107
13.12.2 PRODUCT PORTFOLIO 107
13.12.3 RECENT DEVELOPMENT 107
13.13 MÖLLER MEDICAL GMBH 108
13.13.1 COMPANY SNAPSHOT 108
13.13.2 PRODUCT PORTFOLIO 108
13.13.3 RECENT DEVELOPMENT 108
13.14 NATUS MEDICAL INCORPORATED 109
13.14.1 COMPANY SNAPSHOT 109
13.14.2 PRODUCT PORTFOLIO 109
13.14.3 RECENT DEVELOPMENTS 110
13.15 SOPHYSA 111
13.15.1 COMPANY SNAPSHOT 111
13.15.2 PRODUCT PORTFOLIO 111
13.15.3 RECENT DEVELOPMENTS 112
14 QUESTIONNAIRE 113
15 RELATED REPORTS 116